ABSTRACT
Despite advances in COVID-19 management, it is unclear how to recognize patients who evolve towards death. This would allow for better risk stratification and targeting for early interventions. However, the explosive increase in correlates of COVID-19 severity complicates biomarker prioritisation. To identify early biological predictors of mortality, we performed an immunovirological assessment (SARS-CoV-2 viral RNA, cytokines and tissue injury markers, antibody responses) on plasma samples collected from 144 hospitalised COVID-19 patients 11 days after symptom onset and used to test models predicting mortality within 60 days of symptom onset. In the discovery cohort (n=61, 13 fatalities), high SARS-CoV-2 vRNA, low RBD-specific IgG levels, low SARS-CoV-2-specific antibody-dependent cellular cytotoxicity, and elevated levels of several cytokines and lung injury markers were strongly associated with increased mortality in the entire cohort and the subgroup on mechanical ventilation. Model selection revealed that a three-variable model of vRNA, age and sex was very robust at identifying patients who will succumb to COVID-19 (AUC=0.86, adjusted HR for log-transformed vRNA=3.5; 95% CI: 2.0-6.0). This model remained robust in an independent validation cohort (n=83, AUC=0.85). Quantification of plasma SARS-CoV-2 RNA can help understand the heterogeneity of disease trajectories and identify patients who may benefit from new therapies.
Competing Interest Statement
JBR has served as an advisor to GlaxoSmithKline and Deerfield Capital. These agencies had no role in the design, implementation or interpretation of this study.
Funding Statement
This study was funded by grant 110068-68-RGCV from the American Foundation for AIDS Research (amfAR), by grant VR2-173203 from the Canada COVID-19 Immunity Task Force (CITF), in collaboration with the Canadian Institutes of Health Research (CIHR), by an Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI) 41027 to A.F., D.E.K. and N.C and by le Ministere de l Economie et de l Innovation du Quebec, Programme de soutien aux organismes de recherche et d innovation to A.F., and by the CRCHUM foundation. The Biobanque Quebecoise de la COVID-19 (BQC-19) is supported by the Fonds de recherche Quebec-Sante (FRQS), Genome Quebec and the Public Health Agency of Canada. D.E.K is a FRQS Merit Research Scholar. N.C., M.D. M.C, J.B.R, C.L., M.T. receive a salary award from the FRQS. A.F. and A.P. hold a Canada Research Chair. E.B.R is supported by a COVID-19 excellence scholarship from the Universite de Montreal. S.P.A, J.P. and G.B.B. are supported by CIHR fellowships. R.G. is supported by a MITACS Acceleration postdoctoral fellowship. P.G. is supported by a postdoctoral fellowship from CIHR (415209). The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK, Genome Quebec, the Public Health Agency of Canada and the Fonds de Recherche Quebec Sante (FRQS). GBL is supported by the CIHR, and a joint scholarship from the FRQS and Quebec Ministry of Health and Social Services. TN is supported by the Research Fellowship of Japan Society for the Promotion of Science (JSPS) for Young Scientists. SZ is supported by a CIHR fellowship and a FRQS fellowship. JBR is supported by a FRQS Clinical Research Scholarship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been approved by the IRB of the Centre Hospitalier de l'Universite de Montreal (CHUM) and the IRB of the Jewish General Hospital (JGH) in Montreal, Quebec, Canada.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is provided in the manuscript. Further information and requests for resources and reagents should be directed to the Lead Contact, Kaufmann Daniel daniel.kaufmann{at}umontreal.ca
